Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer.
AuthorsEllis, P A
Clarke, Robert B
Johnston, S R
Smith, I E
AffiliationDepartment of Biochemical Endocrinology, Royal Marsden NHS Trust, London, UK.
MetadataShow full item record
AbstractHormonal breast cancer therapies have traditionally been considered cytostatic, but recent pre-clinical data suggest that anti-oestrogens can induce apoptosis. The aim of this study was to assess whether tamoxifen (TAM) and ICI 182780 (ICI) could induce apoptosis in human breast cancer, and whether this was related to oestrogen receptor status. We measured apoptosis in primary breast cancer patients before and after pre-surgical treatment with 20 mg/day TAM (study 1) or 6 or 18 mg/day ICI (study 2). In each study there was a randomised non-treatment (NT) control group. TAM significantly increased apoptotic index (AI) in ER+ but not in ER- tumours. There was a significant increase in AI following treatment with ICI. Insufficient pairs of samples were available to determine whether this change was confined to ER+ tumours, but in a cross-sectional analysis AI was significantly higher in excision biopsies for ICI-treated than NT patients for ER+ but not ER- tumours. Our results provide clinical evidence that apoptosis may be induced in ER+ primary breast cancer by both non-steroidal and steroidal anti-oestrogens.
CitationInduction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. 1997, 72 (4):608-13 Int. J. Cancer
JournalInternational Journal of Cancer.
- The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling.
- Authors: Martin LA, Pancholi S, Chan CM, Farmer I, Kimberley C, Dowsett M, Johnston SR
- Issue date: 2005 Dec
- Comparative study on the induction of cytostasis and apoptosis by ICI 182,780 and tamoxifen in an estrogen receptor-negative ovarian cancer cell line.
- Authors: Ercoli A, Scambia G, Fattorossi A, Raspaglio G, Battaglia A, Cicchillitti L, Malorni W, Rainaldi G, Benedetti Panici P, Mancuso S
- Issue date: 1998 Mar 30
- Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.
- Authors: Robertson JF, Nicholson RI, Bundred NJ, Anderson E, Rayter Z, Dowsett M, Fox JN, Gee JM, Webster A, Wakeling AE, Morris C, Dixon M
- Issue date: 2001 Sep 15
- ICI 182,780 (Fulvestrant)--the first oestrogen receptor down-regulator--current clinical data.
- Authors: Robertson JF
- Issue date: 2001 Nov
- Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes.
- Authors: McClelland RA, Manning DL, Gee JM, Anderson E, Clarke R, Howell A, Dowsett M, Robertson JF, Blamey RW, Wakeling AE, Nicholson RI
- Issue date: 1996